|Slideshows|May 31, 2019

How the Experts Manage Tardive Dyskinesia

There are a few things that we all agree on, as reflected in a recent consensus statement.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Underdiagnosed and Undertreated: Verena Ramirez Campos, MD, on Tardive Dyskinesia Care

ByVerena Ramirez-Campos, MD

July 23rd 2026

Austedo for Tardive Dyskinesia: Efficacy and Real World Data

ByVerena Ramirez-Campos, MD

July 21st 2026

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

ByLeah Kuntz

May 18th 2026

AI Screening Tool for Tardive Dyskinesia Identifies Disorder and Prompts Clinical Evaluation

ByJessica Walters

April 28th 2026

First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

ByLeah Kuntz

March 27th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

How the Experts Manage Tardive Dyskinesia

Related Content

Underdiagnosed and Undertreated: Verena Ramirez Campos, MD, on Tardive Dyskinesia Care

Austedo for Tardive Dyskinesia: Efficacy and Real World Data

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

AI Screening Tool for Tardive Dyskinesia Identifies Disorder and Prompts Clinical Evaluation

First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD